Raleigh, NC-based Lumexa Imaging Holdings has set the price for its initial public offering (IPO) between $17 and $20 per share of its common stock.
The company, formerly known as US Radiology Specialists, plans to make available some 25 million shares in hopes of raising between $425 million and $500 million. Underwriters have also been granted a 30-day option to purchase up to an additional 3.75 million shares of the company's common stock, according to Lumexa.
Lumexa's shares are expected to begin trading on Nasdaq Global under the symbol LMRI.
Barclays, J.P. Morgan, and Jefferies are acting as joint lead book-running managers for the offering, along with Deutsche Bank Securities, Wells Fargo Securities, and others acting as book-running managers and co-managers.
In its announcement, Lumexa noted that its outpatient imaging network spans 184 centers across 13 states and includes eight joint venture partnerships with health systems.
In August, the company named Russell Stewart, MD, as chief medical officer. Now leading Lumexa's national clinical strategy, Stewart is a practicing, board-certified musculoskeletal radiologist and healthcare executive who most recently served as chief clinical officer at Covera Health.
No date was given for when the IPO will close.
